---
document_datetime: 2023-09-21 20:29:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/pegintron-epar-procedural-steps-taken-authorisation_en.pdf
document_name: pegintron-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4270755
conversion_datetime: 2025-12-24 07:10:15.612797
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

•

Rapporteur's Assessment of additional written information was circulated on 31 January 2000.

•

- During  the  meeting  on  15-17  February  2000  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation for PegIntron.

The  company  SP  Europe,  73,  rue  de  Stalle,  B-1180  Bruxelles submitted  on  8  March  1999  an application  for  Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal Products (EMEA) for PegIntron, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Dr P. Nilsson Co-Rapporteur: Prof. A. Hildebrandt Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 26 March 1999. · The Rapporteur's first assessment report was circulated to all CPMP Members on 4 June 1999. · The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 14 June 1999. · During its meeting on 27-29 July 1999, the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the company on 30 July 1999. · During  its  meeting  on  27-29  July  1999,  the  CPMP  agreed  that  a  GMP  inspection  of  the manufacturing site was not necessary. · The company submitted the responses to the consolidated list of questions on 28 October 1999. · The Rapporteur and the Co-Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 20 December 1999. · The applicant provided supplementary information on 11 January 2000. · The applicant at an oral explanation in the CPMP on 18 January 2000 addressed outstanding questions. · The applicant provided written explanations on 28 January 2000. BWP  discussed remaining quality points on the 8-9 February 2000 and issued a recommendation to CPMP. Medicinal product no longer authorise